Interindividual variability of canalicular ATP‐binding‐cassette (ABC)–transporter expression in human liver

Interindividual variability in hepatic canalicular transporter expression might predispose to the development of hepatic disorders such as acquired forms of intrahepatic cholestasis. We therefore investigated expression patterns of bile salt export pump (BSEP, ABCB11), multidrug resistance protein 3 (MDR3, ABCB4), multidrug resistance associated protein 2 (MRP2, ABCC2) and multidrug resistance protein 1 (MDR1, ABCB1) in healthy liver tissue of a white population. Protein expression levels were correlated with specific single nucleotide polymorphisms (SNPs) in the corresponding transporter genes. Hepatic protein expression levels from 110 individuals undergoing liver resection were assessed by Western blot analysis of liver plasma membranes enriched in canalicular marker enzymes. Each individual was genotyped for the following synonymous (s) and nonsynonymous (ns) SNPs: ABCB11: (ns:1457T>C and 2155A>G), ABCB4: (ns:3826A>G) and ABCC2 (ns:1286G>A,3600T>A and 4581G>A) and ABCB1 (ns:2677G>T/A and s:3435C>T). Transporter expression followed unimodal distribution. However, of all tested individuals 30% exhibited a high expression and 32% a low or very low expression phenotype for at least one of the four investigated transport proteins. Transporter expression levels did not correlate with age, sex, underlying liver disease, or presurgery medication. However, low BSEP expression was associated with the 1457C‐allele in ABCB11 (P = .167) and high MRP2 expression was significantly correlated with the 3600A and 4581A ABCC2 variants (P = .006). In conclusion, the results demonstrate a considerable interindividual variability of canalicular transporter expression in normal liver. Furthermore, data suggest a polymorphic transporter expression pattern, which might constitute a risk factor for the development of acquired forms of cholestatic liver diseases. (HEPATOLOGY 2006;44:62–74.)

[1]  D. Keppler,et al.  Hepatic Secretion of Conjugated Drugs and Endogenous Substances , 2000, Seminars in liver disease.

[2]  P. Borst,et al.  Mammalian ABC transporters in health and disease. , 2002, Annual review of biochemistry.

[3]  D. Keppler,et al.  The rat canalicular conjugate export pump (Mrp2) is down-regulated in intrahepatic and obstructive cholestasis. , 1997, Gastroenterology.

[4]  P. Meier,et al.  Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy. , 2004, Pharmacogenetics.

[5]  K. Zatloukal,et al.  Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. , 2003, Journal of hepatology.

[6]  C. Funk,et al.  Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. , 2001, Molecular pharmacology.

[7]  P. Meier,et al.  Bile salt transporters. , 2002, Annual review of physiology.

[8]  Bruno Stieger,et al.  Enterohepatic bile salt transporters in normal physiology and liver disease. , 2004, Gastroenterology.

[9]  P. Meier,et al.  Enterohepatic transport of bile salts and genetics of cholestasis. , 2005, Journal of hepatology.

[10]  U. Brinkmann,et al.  Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[11]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[12]  C. Meisel,et al.  Frequency of single nucleotide polymorphisms in the P‐glycoprotein drug transporter MDR1 gene in white subjects , 2001, Clinical pharmacology and therapeutics.

[13]  A. Bensadoun,et al.  Assay of proteins in the presence of interfering materials. , 1976, Analytical biochemistry.

[14]  J. Boyer,et al.  Molecular Alterations in Hepatocyte Transport Mechanisms in Acquired Cholestatic Liver Disorders , 2000, Seminars in liver disease.

[15]  Paul T Tarr,et al.  Regulation of Multidrug Resistance-associated Protein 2 (ABCC2) by the Nuclear Receptors Pregnane X Receptor, Farnesoid X-activated Receptor, and Constitutive Androstane Receptor* , 2002, The Journal of Biological Chemistry.

[16]  K. Zatloukal,et al.  Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases , 2001, Hepatology.

[17]  P. Neuvonen,et al.  High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). , 2004, Pharmacogenetics.

[18]  T. Roskams,et al.  Expression and regulation of ABC transporter genes during liver regeneration , 2018 .

[19]  P. Meier,et al.  BSEP and MDR3 haplotype structure in healthy Caucasians, primary biliary cirrhosis and primary sclerosing cholangitis , 2004, Hepatology.

[20]  Richard J. Thompson,et al.  Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis. , 1999, Gastroenterology.

[21]  F. Kuipers,et al.  Isolation and characterization of canalicular and basolateral plasma membrane fractions from human liver. , 1991, Biochimica et biophysica acta.

[22]  Richard J. Thompson,et al.  A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis , 1998, Nature Genetics.

[23]  J. Boyer,et al.  Bile salt export pump is highly conserved during vertebrate evolution and its expression is inhibited by PFIC type II mutations. , 2001, American journal of physiology. Gastrointestinal and liver physiology.

[24]  Jürg Reichen,et al.  The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactions , 2001, Clinical pharmacology and therapeutics.

[25]  S. Grundy.  Mechanism of Cholesterol Gallstones Formation , 1983, Seminars in liver disease.

[26]  J. Boyer,et al.  Molecular pathogenesis of cholestasis. , 2012, The New England journal of medicine.

[27]  Jatinder Lamba,et al.  Disrupted Bile Acid Homeostasis Reveals an Unexpected Interaction among Nuclear Hormone Receptors, Transporters, and Cytochrome P450* , 2001, The Journal of Biological Chemistry.

[28]  R. Houwen,et al.  Benign recurrent intrahepatic cholestasis type 2 is caused by mutations in ABCB11. , 2004, Gastroenterology.

[29]  R. Blevins,et al.  Farnesoid X Receptor Activates Transcription of the Phospholipid Pump MDR3* , 2003, Journal of Biological Chemistry.

[30]  M. Trauner,et al.  Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis. , 2005, Journal of clinical gastroenterology.

[31]  G. Kullak-Ublick,et al.  Coordinate transcriptional regulation of bile acid homeostasis and drug metabolism. , 2005, Archives of biochemistry and biophysics.

[32]  P. Meier,et al.  Functional expression of the canalicular bile salt export pump of human liver. , 2002, Gastroenterology.

[33]  Richard J. Thompson,et al.  The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. , 2002, Gastroenterology.

[34]  E. Jacquemin.  Role of Multidrug Resistance 3 Deficiency in Pediatric and Adult Liver Disease: One Gene for Three Diseases , 2001, Seminars in liver disease.

[35]  P. Meier,et al.  Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. , 2000, Gastroenterology.

[36]  Oliver Burk,et al.  Cytochrome P450 3A4 and P‐glycoprotein Expression in Human Small Intestinal Enterocytes and Hepatocytes: A Comparative Analysis in Paired Tissue Specimens , 2004, Clinical pharmacology and therapeutics.